Testosterone Drug Overuse: FDA Warning

An increasing number of men are using testosterone drugs to enhance their physical performance or treat medical issues such as low T and other age-related issues. Studies have revealed that testosterone drugs like Lilly Axiron and AbbVie’s Angrogel have increased their sales to over $2 million. According to research, nearly one million men since 2000 had tested their T levels and half a million of them started using hormone replacement therapy. Today, men who take these drugs have increased fourfold than they did in 2000. However, a warning has been issued to doctors by the Food and administration (FDA) against over- prescribing testosterone drugs to men.

Low Testosterone levels in Men

The testosterone levels of men naturally decline after 40 years of age. Low level of testosterone can make men have issues such as lower bone density and decreased energy. Additionally, levels of testosterone levels can change every hour due to various environmental factors such as sexual arousal and stress. However, due to the successful advertising campaigns used to promote testosterone drugs, many men feel that these drugs are a solution to all their problems.

Testosterone drug Overuse: FDA Warning

Testosterone moleculaThe Food Drug Administration have cautioned buyers that these drugs have not been established effective or safe for age-related issues like fatigue and low- libido. The present drug labeling is vague, allowing companies to promote these drugs to otherwise healthy men who have lower than normal testosterone levels. The agency states that the drugmakers in their labeling and promotions must make it clear that the drugs are only approved to treat low testosterone levels caused by injury or disease and not by aging. Additionally, since taking testosterone drugs can increase the risk of cardiovascular problems, heart attack or stroke, drugmakers should warn the users about the potential risks by adding information to their prescribing labels.

Testosterone therapy in the US is approved by the FDA for disorders in which testicles fail to produce testosterone as a result of chemotherapy or due to genetic problems. However, the agency does not approve using these drugs to treat age- related issues. The FDA has stated that drugmakers should reveal the potential risks that can be caused when taking these drugs and had directed for further investigation to be carried out. The FDA warning is the result of a re-examination of the safety of testosterone drugs. Based on two clinical results, FDA and its panel have concluded that drug labeling needs to be changed.

Back to Top